ACS Medicinal Chemistry Letters

PATENT HIGHLIGHT

pubs.acs.org/acsmedchemlett

Pyridopyrimidines as Inhibitors of Hepatitis C Virus

Gerard Rosse*

Structure Guided Chemistry, Dart Neuroscience LLC, 7473 Lusk Boulevard, San Diego, California 92121, United States, and Adjunct Associate Professor, Department of Pharmacology and Physiology, College of Medicine, Drexel University, New College Building, 245 North 15th Street, Philadelphia, Pennsylvania 19102, United States

Title:	Pyridopyrimidines as Inhibitors of Hepatitis C Virus		
Patent/Patent Application Number:	WO 2013090840 A1	**Publication date:**	June, 20, 2013
Priority Application:	US 2011−576284P	**Priority date:**	December 15, 2011
Inventors:	Jin, H.; Kim, C. U.; Li, J.		
Assignee Company:	Gilead Sciences, Inc., USA		
Disease Area:	Hepatitic C Virus infection	**Biological Target:**	
Summary:	This application claims pyridopyrimidine analogues for the treatment and prevention of HCV infections.		

Important Compound Classes:



Key Structures:



Compound 1



Compound 2



Compound 3



Compound 4



Compound 5



Compound 6



Compound 7

Special Issue: HCV Therapies

Received: October 15, 2013
Published: October 24, 2013

Recent Review Articles:

Biological Assay: Effect of compounds was evaluated using HCV replicon assays developed from H77 (GT1a), Con1 (GT1b), or JHF-1 (GT2a) strain.

Pharmacological Data: Seven compounds were tested for antiviral activity in HCV replicon assay The unit for the EC_{50} is not described.

Compound	HCV replicon 1A EC_{50}	HCV replicon 2A EC_{50}	HCV replicon 1B EC_{50}
1	1295.5	0.684	5.566
2	4444.4	18.447	444.44
3	2991.7	2.495	42.367
4	94.726	0.165	1.075
5	1882.3	0.507	0.756
6	4444.4	3.879	4.502
7	300.77	0.092	0.461

Synthesis: The synthesis of seven compounds is described.

AUTHOR INFORMATION

Corresponding Author
*E-mail: grosse@dartneuroscience.com.

Notes
The authors declare no competing financial interest.